Avecho resumes final-stage recruitment for pivotal insomnia trial as licensing talks advance
AVE: $0.015 +7.14% · MC: $46M
Avecho Biotechnology has restarted recruitment for the final cohort of its Phase III insomnia trial after an interim review recommended continuing to the study’s original target; the company expects recruitment to take about a year. Avecho says licensing discussions with multiple parties for markets outside Australia are progressing, while its cash position was $5 million at quarter-end.

Comments